JP7767651B2 - Ｇｌｐ１医薬組成物 - Google Patents

Ｇｌｐ１医薬組成物

Info

Publication number
JP7767651B2
JP7767651B2 JP2024566219A JP2024566219A JP7767651B2 JP 7767651 B2 JP7767651 B2 JP 7767651B2 JP 2024566219 A JP2024566219 A JP 2024566219A JP 2024566219 A JP2024566219 A JP 2024566219A JP 7767651 B2 JP7767651 B2 JP 7767651B2
Authority
JP
Japan
Prior art keywords
fluoro
amount
composition
sdd
methylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024566219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515706A (ja
JP2025515706A5 (https=
Inventor
ジョセフ バーンズ，リー
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2025515706A publication Critical patent/JP2025515706A/ja
Publication of JP2025515706A5 publication Critical patent/JP2025515706A5/ja
Priority to JP2025182180A priority Critical patent/JP2026021422A/ja
Application granted granted Critical
Publication of JP7767651B2 publication Critical patent/JP7767651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024566219A 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物 Active JP7767651B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182180A JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340,591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182180A Division JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Publications (3)

Publication Number Publication Date
JP2025515706A JP2025515706A (ja) 2025-05-20
JP2025515706A5 JP2025515706A5 (https=) 2025-06-18
JP7767651B2 true JP7767651B2 (ja) 2025-11-11

Family

ID=86732348

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024566219A Active JP7767651B2 (ja) 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物
JP2025182180A Pending JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182180A Pending JP2026021422A (ja) 2022-05-11 2025-10-29 Ｇｌｐ１医薬組成物

Country Status (17)

Country Link
US (1) US20250302809A1 (https=)
EP (1) EP4522129A1 (https=)
JP (2) JP7767651B2 (https=)
KR (1) KR20250002778A (https=)
CN (1) CN119173255A (https=)
AR (1) AR129296A1 (https=)
AU (1) AU2023269995A1 (https=)
CA (1) CA3253043A1 (https=)
CL (1) CL2024003392A1 (https=)
CO (1) CO2024015285A2 (https=)
DO (1) DOP2024000232A (https=)
IL (1) IL316629A (https=)
JO (1) JOP20240245A1 (https=)
MX (1) MX2024013839A (https=)
PE (2) PE20260136A1 (https=)
TW (2) TW202508581A (https=)
WO (1) WO2023220109A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202540124A (zh) * 2023-11-21 2025-10-16 大陸商江蘇恆瑞醫藥股份有限公司 雜環類化合物、其製備方法及其在醫藥上的應用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018056453A1 (ja) 2016-09-26 2018-03-29 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
JP2019099571A (ja) 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
WO2020247160A1 (en) 2019-05-14 2020-12-10 Vertex Pharmaceuticals Incorporated Condensed tryciclic pyrroles as alpha-1 antitrypsin modulators
JP2022508317A (ja) 2018-12-07 2022-01-19 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
WO2022055880A1 (en) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
JP2025516547A (ja) 2022-05-11 2025-05-30 イーライ リリー アンド カンパニー Ｇｌｐ１錠剤組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434641A1 (en) * 2001-01-18 2002-08-22 Pharmacia And Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018056453A1 (ja) 2016-09-26 2018-03-29 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
JP2019099571A (ja) 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2022508317A (ja) 2018-12-07 2022-01-19 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
WO2020247160A1 (en) 2019-05-14 2020-12-10 Vertex Pharmaceuticals Incorporated Condensed tryciclic pyrroles as alpha-1 antitrypsin modulators
WO2022055880A1 (en) 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator
JP2025516547A (ja) 2022-05-11 2025-05-30 イーライ リリー アンド カンパニー Ｇｌｐ１錠剤組成物

Also Published As

Publication number Publication date
MX2024013839A (es) 2024-12-06
CA3253043A1 (en) 2023-11-16
CN119173255A (zh) 2024-12-20
CL2024003392A1 (es) 2025-03-14
AR129296A1 (es) 2024-08-07
JP2025515706A (ja) 2025-05-20
PE20251285A1 (es) 2025-05-14
JP2026021422A (ja) 2026-02-10
JOP20240245A1 (ar) 2024-11-05
EP4522129A1 (en) 2025-03-19
PE20260136A1 (es) 2026-01-21
IL316629A (en) 2024-12-01
DOP2024000232A (es) 2024-12-30
KR20250002778A (ko) 2025-01-07
US20250302809A1 (en) 2025-10-02
CO2024015285A2 (es) 2024-11-28
WO2023220109A1 (en) 2023-11-16
AU2023269995A1 (en) 2024-11-14
TW202410894A (zh) 2024-03-16
TW202508581A (zh) 2025-03-01
TWI867526B (zh) 2024-12-21

Similar Documents

Publication Publication Date Title
JP7767651B2 (ja) Ｇｌｐ１医薬組成物
JP5794650B2 (ja) 難溶性薬物の溶解性改善製剤
AU2005324132B2 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
AU2004305226B2 (en) Method for the production of a solid, orally applicable pharmaceutical composition
CN101983054B (zh) 含有咪达那新的口腔内迅速崩解性片剂
TW201446286A (zh) 抗病毒化合物之固態分散調製劑
JP2025516547A (ja) Ｇｌｐ１錠剤組成物
KR102333463B1 (ko) 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
WO2001085135A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF
KR100663079B1 (ko) 이트라코나졸 함유 고체분산체의 제조방법
WO2009050720A1 (en) Pharmaceutical composition of orlistat
EP4279075B1 (en) A pharmaceutical composition comprising elagolix
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
TWI746418B (zh) 包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇鈉之醫藥劑型
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin
WO2025164725A1 (ja) ジヒドロピリジノン誘導体を含有する医薬組成物
WO2007049626A1 (ja) カベルゴリン含有経口固形製剤
JP2025122084A (ja) レボドパ持続性製剤
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150